Dive into the archives.
- Study Finds that most neurologists plan to prescribe oral MS drugs when approved this year
Majestic Research Study Indicates that Neurologists’ Apprehension Regarding Side Effects Won’t Stop Them from Prescribing New Oral MS Drugs, but Concerns Will Likely Relegate Their Use to Second- or Third-Line Therapy NEW YORK–(BUSINESS WIRE)–In a study published this week by Majestic Research, almost 60% of neurologists expressed unaided concern about the side effects/safety of oral MS [...]
- Sanofi’s Teriflunomide Shows Promise for RRMS
Sanofi-aventis (NYSE:SNY) recently announced clinical success with teriflunomide, the investigational drug it is developing for the treatment of relapsing multiple sclerosis (RMS). This announcement followed a 2-year clinical trial, in which teriflunomide was found to significantly improve the annualized relapse rate (ARR) of RMS in a group patients receiving the orally administered teriflunomide, when compared [...]
- Quebec willing to test MS treatment
A call for a national trial of a controversial M-S treatment has gained support. Quebec Health Minister Yves Bolduc says the province would be willing to join a national clinical trial of the so-called liberation procedure. The treatment is based on an unproven theory that blocked veins in the neck or spinal cord are to [...]
- ‘Placebo effect’ a concern with CCSVI
Canadians experts say they fear stories of miraculous results from a controversial new MS treatment could be more about the “placebo effect” than an actual breakthrough — fears given new credence by two discouraging new European studies. “I appreciate what people are going through — living with MS can be a terrible thing and they [...]
- New research fails to support CCSVI theory
THURSDAY, Aug. 5 (HealthDay News) — An emerging hypothesis suggests that the demyelination of cerebral veins that characterizes multiple sclerosis (MS) may be caused by chronic cerebrospinal venous insufficiency (CCSVI), but research published in the August issue of the Annals of Neurology does not concur with the hypothesis. Peter Sundström, M.D., of Umea University in [...]
